In agreement, the EMT gene signature is a biomarker that positively determines the sensitivity of KRAS-mutant and pan-solid cancer cells to various HSP90 inhibitors (Fig. 1h, i) and high levels of HSP90AA1 (HSP90) are associated with tumor progression, poor survival, and high recurrence rates in KRAS-mutant and pan-cancers (Fig. 1j; Supplementary Fig. 3B–E). The gene discussed is HSP90AA1; the disease is cancer.